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ABSTRACT
The individualized treatment of type 2 diabetes
mellitus, using various glucagon-like peptide
receptor agonists (GLP1RAs), has recently been
described. As experience with existing GLP1RAs
grows, and as newer molecules in the
development pipeline continue to progress,
interest related to these drugs continues to
grow. This article describes a person-centered
approach, using the bio-psychosocial model of
health, to help individualized decision making
related to choice of GLP1RA. It utilizes an
evidence-based approach to discuss various
biomedical and psychosocial factors which
may influence choice of GLP1RA.
Keywords: Glucagon-like peptide 1 receptor
agonists; GLP1RAs; Patient centered; Type 2
diabetes
INTRODUCTION
Glucagon-like peptide 1 receptor agonists
(GLP1RAs) have become an accepted part of
the diabetes pharmaco-therapeutic landscape.
The GLP1RAs are included in guidelines from
various professional bodies such as the
International Diabetes Federation (IDF), the
American Diabetes Association (ADA),
European Association for Study of Diabetes
(EASD), and American Association of Clinical
Endocrinologists (AACE). GLP1RAs can be used
as second-line and third-line agents, in
combination with metformin and insulin.
There is also evidence to suggest that
GLP1RAs should be used earlier on in the
natural history of diabetes, so as to utilize their
full potential [1].
CLASSIFICATION
An increasing number of GLP1RAs are available
for use, or are in advanced phases of
development. While they have earlier been
divided according to chemical structure,
GLP1RAs can also be classified based on their
duration of action (Table 1). This approach
makes it easier to compare and contrast the
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various pharmacokinetic and
pharmacodynamic properties of these drugs.
Short-acting GLP1RAs are those with a half-life
of \12 h, which requires daily or twice daily
administration [2, 3]. Intermediate-acting
GLP1RAs are those with a half-life of [12 h [4],
which allow once daily injection. Long-acting
GLP1RAs have half-lives of[24 h [5, 6] and can
be injected as once-weekly doses. The once-
daily GLP1RA, viz, liraglutide and lixisenatide,
are also being developed as fixed ratio co-




Various GLP1RAs have been utilizing differing
strategies to prolong or protract their duration
of action. The shortest-acting GLP1RA, viz
exenatide and lixisenatide [3, 7], achieve this
by exchanging amino acids at the N2 and N3
positions, thus making them resistant to
breakdown by dipeptidyl peptidase 4 (DPP4).
The renal elimination of the molecule,
however, continues as per physiology, and so
drug levels fall to baseline prior to the next
injection. The short half-life of 2–4 h means
that peak concentrations are maintained for
just 6 h.
Liraglutide achieves a longer half-life
(12–13 h) and duration of action, by having a
fatty acid side chain. This allows it to bind non-
covalently to plasma albumin. This increases its
size and slows down release of the GLP 1 moiety
from plasma albumin, thus prolonging its
action [8]. Albiglutide uses a similar albumin-
binding based approach, but binds in a covalent
manner to the protein. The long half-life of the
albumin–GLP1 conjugate allows for a long
duration of action and once-weekly
administration [5, 9]. Dulaglutide employs a
novel mechanism of protraction of action. It
conjugates GLP-1 with the Fc fragment of IgG
and thus achieves a longer duration of action
[10, 11]. Exenatide long-acting release (LAR) is a
chemical modification of exenatide, which is
coupled to microspheres that allow slow and
steady release of the molecule from its
subcutaneous site [6].
PATIENT-CENTERED PHILOSOPHY
Current guidelines promote a patient-centered
approach to the management of diabetes. In
essence, a patient-centered approach implies
crafting of a management strategy which
involves the patient and is respectful of his or
her opinion. Viewed through a larger prism,
patient-centered care assumes acceptance of the
bio-psychosocial model of disease. It is
understood that biomedical, psychological, and
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social factors impact not only the presentation of
diabetes, but also its management. Apart from
biological characteristics, psychosocial reality
should be taken into consideration while
planning a therapeutic regime.
The varieties of GLP1RAs available today and
their unique pharmacological properties allow a
patient-centered choice to be made in this class
of drugs. This is similar to the approach




Various factors which influence the choice of a
GLP1RA can be categorized according to the
bio-psychosocial model (Table 2).
BIOMEDICAL FACTORS
The biomedical factors which inform the
appropriate choice of GLP1RA include efficacy,
Table 2 Comparison of GLP1RA
Short-acting GLP1RA Intermediate- and long-acting
GLP1RA
Control of fasting glycemia Suitable More suitable
Control of postprandial glycemia More suitable Suitable
Control of HbA1c Effective Effective
Frequency of dosage Daily/twice daily Weekly/once daily
Combination with basal insulin Complementary effect Complementary effect for liraglutide
Combination with premixed insulin May show beneﬁcial effect May show complementary effect
Use as directly observed therapy (DOT) Not feasible Feasible
Gauge of needle Thin (31G, 32G) Thick (23G) for exenatide LAR
Injection technique Simple Requires manual dexterity for
exenatide LAR, injection technique
is also simple for liraglutide, titrated
with the same pen
Injection site reactions Rare Common, seldom with liraglutide
Gastrointestinal symptoms More common Less common
Increase in pulse rate Less common More common
Weight loss Effective Effective
Improvement in lipid proﬁle Minimal Minimal
Antibody formation Relatively high with exenatide Relatively high with exenatide LAR;
low for liraglutide
Ability to stop in case
of adverse events
Retained Lost for once-weekly injections
GLP1RA glucagon-like peptide 1 receptor agonists, LAR long-acting release
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safety, tolerability, and versatility in
combination with insulin.
Efficacy is an important determinant choice.
The shorter-acting GLP1RAs have a greater
effect on postprandial glycemia, while the
longer-acting molecules lower fasting glucose
to a greater extent. Short-acting GLP1RAs delay
gastric emptying, decrease the rate of glucose
delivery to the duodenum, blunt postprandial
glycemia excursions, and reduce insulin levels
as well. They also help in reducing postprandial
lipid levels. However, their short duration of
action means that optimal glucose control may
not be achieved over the full 24 h [12].
Exenatide lowers breakfast and post-dinner
glucose levels to a much greater degree than
post-lunch excursions. This is expected with a
twice-daily dose, keeping its pharmacokinetic
profile in mind. The HbA1c reduction varies
from 0.8% to 1.5% with the recommended dose
of 10 lg twice daily [13–16].
Lixisenatide is associated with modest
improvements in postprandial glucose after
each meal, and in HbA1c (0.7–1.0%), with a
once-daily dose of 20 lg [17–19]. This drug has a
lower risk of nausea, vomiting and
hypoglycemia as compared to exenatide.
The intermediate-acting liraglutide, used in a
dose of 1.2–1.8 mg/day, improves both fasting
and postprandial glucose values, leading to a
1.1–1.8% reduction of HbA1c [1, 20–23].
Gastrointestinal effects and hypoglycemia are
less common than with exenatide; liraglutide
also exhibits added benefits of low antibody
formation, reduction in systolic blood pressure,
and greater weight loss [24]. The drug is
associated with a slight increase in pulse rate,
and the impact of this positive chronotropic
effect on cardiovascular health is uncertain.
Intermediate- and long-acting GLP1RAs
exhibit greater effect on fasting glucose levels,
as they continue to act during the nighttime.
They do not have a significant effect on gastric
motility, as the initial slowing is abolished due
to tachyphylaxis. Shorter-acting GLP1RAs do
not suffer from tachyphylaxis because of their
intermittent action [3].
The intermediate-acting and long-acting
GLP1RAs cover all 24 h glucose control including
fasting glucose. The short-acting GLP1RAs
probably also achieve weight loss through central
effects mediated via the hypothalamus.
Longer-acting drugs such as albiglutide have
a lower HbA1c reduction (0.78% vs. 0.99%) and
lower body weight reduction (-0.62 vs.
-2.21 kg) probably because of the larger size
which prevents entry into the central nervous
system [25, 26]. The weekly dose of 30 mg,
facilitated by a long half-life of 6–8 days, is
associated with low rates of nausea and
hypoglycemia, but significant local injection
site reaction [27, 28].
Dulaglutide, too, can be administered once
weekly with its half-life of 90 h [11, 12].
Significant HbA1c reduction (1.35%) and
weight reduction (2.43 kg) have been noted
with doses of 1 mg once weekly for the first
4 weeks, followed by 2 mg weekly for 12 weeks.
Nausea and a positive chronotropic effect are
noted with this long-acting GLP1RA.
Injection site reactions such as nodule
formation are most often observed with
exenatide LAR, which also needs thicker gauge
needle for administration [29–32]. While
diarrhea occurs more frequently with longer-
acting compounds, nausea seems to be more
common with short-acting GLP1RA. This may
be a function of their effect on gastrointestinal
motility. Gastroparesis may be an indication to
choose intermediate- or longer-acting GLP1RA,
while being a relative contraindication for the
shorter-acting GLP1RA.
The duration of action of GLP-1 analogs
determines the possible combination with a
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short-acting insulin or a basal insulin. The
short-acting exenatide can be given with a
basal insulin as it has a greater effect on
postprandial glucose levels because of its
shorter half-life. In contrast, the longer-acting
GLP-1 analogs exert greater effect on fasting
glucose levels than shorter-acting GLP-1
analogs. Selection of a GLP1RA would depend
on which glycaemic disturbance is more
predominant [33].
The possible combination of a long-acting
GLP-1 analog with a short-acting insulin would
also offer the advantages of complementary
pharmacologies and could theoretically reduce
both fasting and postprandial blood glucose
levels.
A positive chronotropic effect has been
noted with intermediate- and long-acting
GLP1RA, but not with the short-acting
molecules. The short-acting drugs are also
associated with greater improvements in
postprandial lipid excursions: these factors
may encourage their use in specific patients
with cardiovascular morbidity.
Another biomedical factor which determines
the choice of GLP analog prescribed is the effect
on autonomic functions. Liraglutide has less
effect on gastrointestinal motility than short-
acting GLP-1 analogs like exenatide and
lixisenatide [34, 35]. Thus, liraglutide is a
better choice in diabetic patients with
impaired autonomic functions. On the other
hand, exenatide and lixisenatide can be
prescribed in patients with no signs and
symptoms of gastroparesis.
Thus, careful assessment of the expected
efficacy (fasting vs. postprandial vs. overall
glycemic control), anticipated risk of side
effects (gastrointestinal symptoms,
hypoglycemia, antibody formation, injection
site reactions), effect on weight, cost and
comorbid conditions (dyslipidaemia,
hypertension) can help individualize the
choice of GLP1RA.
PSYCHOSOCIAL FACTORS
Psychosocial factors may also influence the
choice of a GLP1RA. The ability of the patient
to self-inject, to adhere to pre-specified times of
injection(30 min before meals for exenatide),
manual dexterity, frequency of contact with
health-care providers, meal pattern followed,
and adherence to therapy are some of these
issues.
For a person who can self-inject, all GLP1RAs
are equally feasible for use. Use of exenatide
LAR, however, requires some amount of manual
dexterity, as it has to be self-mixed prior to
injection. For those unable or unwilling to self-
inject and dependent upon a caregiver for the
same, a once-weekly injection of long-acting
GLP1RA represents a useful therapeutic strategy.
This once-weekly injection can be administered
as directly observed therapy (DOT), akin to that
used in tuberculosis control programs. This
approach has the added advantage of
encouraging regular patient provider contact,
which facilitates early detection of adverse
events and complications, and encourages
more efficient lifestyle modification. It is also
helpful in patients who may not adhere to more
frequently administered therapy.
Meal pattern also informs the choice of a
GLP1RA. Patients who consume heavy
breakfast and dinner may benefit from
exenatide twice daily, while those who take a
light dinner may wish to take lixisenatide.
Liraglutide’s profile is such that it will be
effective with all meal patterns. Patients with
irregular meal habit and lifestyles, which put
them at risk of hypoglycemia, will respond to
once-weekly drugs without major safety
concerns.
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The different GLP-1 analogs have been
compared with respect to the improvement in
the quality of life and treatment satisfaction.
The increase in patients’ treatment satisfaction
from baseline is significantly higher with 1.8 mg
liraglutide than with sitagliptin, but the
increase with 1.2 mg liraglutide versus
sitagliptin is not significant [36]. No difference
was perceived in the convenience of treatment
between the oral versus injectable. Compared to
patients on traditional therapy which was
insulin, patients taking exenatide showed
greater satisfaction, increased well-being and
decreased anxiety [37]. Liraglutide 1.8 mg
versus glimepiride improves psychological and
emotional well-being and health perceptions by
reducing anxiety and worry associated with
weight gain [38].
CONCLUSION
The preceding discussion provides a reasonably
robust evidence-based assessment upon which
an appropriate GLP1RA can be chosen or
changed. Further research and experience will
help utilize GLP1RA therapy in the best
possible manner for the benefit of people
with diabetes.
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